Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | 10% owner | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Emerald Hill Ventures SARL SPF. | 3,186,576 |
Reported balance
After 2026-06-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 50,000 · Balance 3,186,576 F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.29 to $18.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF. |
| Common StockSEC Table I · non-derivative | Direct | 109,321 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 109,321 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.29 to $18.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 17:41 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 50,000 | $18.32 | $916,000.00 |
DisclosureSEC source: 0001104659-26-079793 · tm2619552-2_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 3,186,576 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.29 to $18.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 72,836 | $6.28 | $457,410.08 |
DisclosureSEC source: 0001104659-25-103522 · tm2529599-1_4seq1.xml · nonDerivative · entry 3 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 3,136,576 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF. Read SEC document |
| October 24, 2025 Filed Oct 29, 2025 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 35,034 | $6.15 | $215,459.10 |
DisclosureSEC source: 0001104659-25-103522 · tm2529599-1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 3,063,740 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF. Read SEC document |
| October 23, 2025 Filed Oct 29, 2025 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 46,900 | $6.06 | $284,214.00 |
DisclosureSEC source: 0001104659-25-103522 · tm2529599-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 3,028,706 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:14 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,603 | $7.99 | $44,767.97 |
DisclosureSEC source: 0001104659-25-062168 · tm2518659-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,981,806 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 13:50 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 28,043 | $8.05 | $225,746.15 |
DisclosureSEC source: 0001104659-25-060965 · tm2518418-1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,976,203 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.91 to $8.11. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 13:50 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,399 | $8.11 | $43,785.89 |
DisclosureSEC source: 0001104659-25-060965 · tm2518418-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,948,160 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 12, 2025 Filed May 13, 2025 22:36 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 21,167 | $8.11 | $171,664.37 |
DisclosureSEC source: 0001104659-25-047938 · tm2514962-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,942,761 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.11 to $8.12. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 09, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,395 | $8.98 | $48,425.52 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 6 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,936,594 F3 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to include transactions that occurred on May 9, 2025. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 09, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 9,817 | $8.90 | $87,411.55 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 5 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,931,199 F3 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to include transactions that occurred on May 9, 2025. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 09, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 9,850 | $8.95 | $88,127.95 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 4 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,921,382 F3 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to include transactions that occurred on May 9, 2025. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,400 | $8.65 | $20,760.00 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 8 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,911,532 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 100 | $8.65 | $865.00 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 7 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,909,132 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 100 | $8.65 | $865.00 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 6 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,909,032 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 50 | $8.65 | $432.50 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 5 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,908,932 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,400 | $8.97 | $21,528.00 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 3 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,911,532 F2 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to correct the price of securities acquired by the reporting in the reported transactions. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 100 | $8.71 | $871.00 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,909,132 F2 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to correct the price of securities acquired by the reporting in the reported transactions. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 08, 2025 Filed May 12, 2025 13:25 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 100 | $8.99 | $899.00 |
DisclosureSEC source: 0001104659-25-047089 · tm2514779-1_4aseq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,909,032 F2 · price: The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to correct the price of securities acquired by the reporting in the reported transactions. F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 9,614 | $8.64 | $83,064.96 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 4 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,908,882 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,703 | $8.40 | $22,705.20 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 3 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,899,268 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 06, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 10,104 | $8.64 | $87,298.56 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,896,565 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| May 06, 2025 Filed May 9, 2025 22:53 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,340 | $8.40 | $19,656.00 |
DisclosureSEC source: 0001104659-25-046882 · tm2514669-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,886,461 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 22:58 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 240,000 | $5.00 | $1,200,000.00 |
DisclosureSEC source: 0001104659-25-011588 · tm256199-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Emerald Hill Ventures SARL SPF. Disclosed balance after: 2,884,121 F1 · balance_after: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 22:37 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 17,000 | $4.70 | $79,900.00 |
DisclosureSEC source: 0001104659-24-129009 · tm2431244-1_4aseq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,644,121 F1 · balance_after: The original Form 4, filed on December 16, 2024, is being amended by this Form 4 amendment to include a transaction that occurred on December 12, 2024, and to correct the amount of securities beneficially owned by the reporting person as a result of the reported transactions. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 13:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 17,000 | $4.70 | $79,900.00 |
DisclosureSEC source: 0001104659-24-128688 · tm2431126-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,612,000 Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:37 UTC Amendment | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 32,121 | $4.64 | $149,041.44 |
DisclosureSEC source: 0001104659-24-129009 · tm2431244-1_4aseq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,627,121 Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 860 | $13.88 | $11,936.80 |
DisclosureSEC source: 0001104659-23-086060 · tm2322480-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,595,000 Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,584 | $13.91 | $35,943.44 |
DisclosureSEC source: 0001104659-23-085603 · tm2322388-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,594,140 Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,556 | $13.98 | $21,752.88 |
DisclosureSEC source: 0001104659-23-085087 · tm2322292-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,591,556 Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 10:52 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 10,000 | $13.97 | $139,700.00 |
DisclosureSEC source: 0001104659-23-084523 · tm2322208-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,590,000 Read SEC document |
| July 21, 2023 Filed Jul 24, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,844 | $14.61 | $41,550.84 |
DisclosureSEC source: 0001104659-23-083470 · tm2321778-1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,580,000 Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,394 | $14.40 | $77,673.60 |
DisclosureSEC source: 0001104659-23-083470 · tm2321778-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,577,156 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.10 to $14.42. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 10:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 8,000 | $14.84 | $118,720.00 |
DisclosureSEC source: 0001104659-23-082536 · tm2321693-2_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,571,762 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.76 to $14.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 12:06 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 9,149 | $14.84 | $135,771.16 |
DisclosureSEC source: 0001104659-23-082196 · tm2321610d1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,563,762 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.71 to $14.94. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 3,285 | $15.09 | $49,570.65 |
DisclosureSEC source: 0001104659-23-080572 · tm2321205d1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,554,613 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.05 to $15.11. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 10,000 | $15.36 | $153,600.00 |
DisclosureSEC source: 0001104659-23-080178 · tm2321109-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,551,328 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.25 to $15.46. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 8,948 | $15.19 | $135,920.12 |
DisclosureSEC source: 0001104659-23-079339 · tm2320922-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,541,328 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.07 to $15.19. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 12:04 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 3,179 | $15.01 | $47,716.79 |
DisclosureSEC source: 0001104659-23-078942 · tm2320821-2_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,532,380 Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 11:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,176 | $15.52 | $18,251.52 |
DisclosureSEC source: 0001104659-23-078475 · tm2320683d1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,529,201 Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 12:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 16,760 | $16.46 | $275,869.60 |
DisclosureSEC source: 0001104659-23-075031 · tm2319737-2_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,528,025 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 12:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 73,175 | $17.43 | $1,275,440.25 |
DisclosureSEC source: 0001104659-23-074561 · tm2319640-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,511,265 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $16.9149 to $17.7559. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 12:59 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 6,999 | $17.73 | $124,092.27 |
DisclosureSEC source: 0001104659-23-074060 · tm2319541d1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,438,090 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 12:59 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 6,091 | $17.71 | $107,871.61 |
DisclosureSEC source: 0001104659-23-074060 · tm2319541d1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,431,091 Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 12:25 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 12,700 | $17.75 | $225,425.00 |
DisclosureSEC source: 0001104659-23-072614 · tm2319007-4_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,425,000 Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 10:46 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 31,724 | $17.71 | $561,832.04 |
DisclosureSEC source: 0001104659-23-071869 · tm2318934-1_4seq1.xml · nonDerivative · entry 2 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,412,300 Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 10:46 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 400 | $17.54 | $7,016.00 |
DisclosureSEC source: 0001104659-23-071869 · tm2318934-1_4seq1.xml · nonDerivative · entry 1 Mosseri Marlio Charles · CIK 0001806384 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380,576 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.